Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 593

[60] Deboer AG, Devries HE, Delange ECM, Danhof M, Kuiper J, Breimer DD. Drug trans-
port to the brain— in vitro versus in vivo approaches. J Control Release 1994;28:259-63.
[61] Bodor N, Buchwald P. Brain-targeted drug delivery: experiences to date. Am J Control
Drug Deliv 2003;1:13-26.
[62] Doan KMM, Humphreys JE, Webster LD, Wring SA, Shampine LJ, Searbit-Singh CJ,
et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous
system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303:1029-37.
[63] Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a deter-
minant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res
1994;11:412-9.
[64] Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug
delivery: preparation, properties and interactions with cells. Adv Drug Delivery Rev 2002;
54:135-47.
[65] Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics
with molecular Trojan horses. J Control Release 2007;122:345-8.
[66] Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H,
Lehtolainen-Dalkilic P, et al. Avidin fusion protein-expressing lentiviral vector for tar-
geted drug delivery. Hum Gene Ther 2009;20:871-2.
[67] De Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain
barrier. Clin Pharmacokinet 2007;46:553-76.
[68] Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol
Lett 2009;31:1-11.
[69] Pardridge WM, Kumagai AK, Eisenberg JB. Chimeric peptides as a vehicle for peptide
pharmaceutical delivery through the blood-brain barrier. Biochem Biophys Res Commun
1987;146:307-13.
[70] Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive mediated endocytosis of cation-
ized albumin and a -endorphin-cationized albumin chimeric peptide by isolated brain
capillaries. J Biol Chem 1987;262:15214-9.
[71] Pardridge WM, Triguero D, Buciak JL, Yang J. Evaluation of cationized rat albu-
min as a potential blood-brain barrier drug transport vector. J Pharmacol Exp Ther
1990;255:893-99.
[72] Fukuta M, Okada H, Iinuma S, Yanai S, Toguchi H. Insulin fragments as a carrier for
peptide delivery across the blood-brain barrier. Pharm Res 1994;11:1681-8.
[73] Granholm AC, Backman C, Bloom F, Ebendal T, Gerhardt GA, Hoffer B, et al. NGF and
antitransferrin receptor antibody conjugate: short- and long-term effects on survival of cho-
linergic neurons in intraocular septal transplants. J Pharmacol Exp Ther 1994;268:448-59.
[74] Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. Pharmacologic effects
in vivo in brain by vector mediated peptide drug delivery. Proc Natl Acad Sci USA
1993;90:2618-22.
[75] Pardridge WM, Kang YS, Buciak JL. Transport of human recombinant brain-derived neu-
rotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector medi-
ated peptide drug delivery. Pharm Res 1994;11:738-46.
[76] Triguero D, Buciak JB, Yang J, Pardridge WM. Blood brain barrier transport of cation-
ized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad
Sci USA 1989;86:4761-5.
[77] Kang YS, Pardridge WM. Brain delivery of biotin bound to a conjugate of neutral avidin
and cationized human albumin. Pharm Res 1994;11:1257-64.
[78] Boado RJ, Zhang Y, Wang Y, Pardridge WM. GDNF fusion protein for targeted-drug
delivery across the human blood-brain barrier. Biotechnol Bioeng 2008;100:387-96.